Breslow's Hypothesis: Melanoma Thickness as the Primary Prognostic Indicator
Breslow's hypothesis establishes that the vertical thickness of a melanoma, measured in millimeters from the granular layer of the epidermis to the deepest point of tumor invasion, is the single most powerful prognostic factor for predicting survival and disease progression in primary cutaneous melanoma.
The Core Concept
Breslow thickness (also called the Breslow index) represents a fundamental shift in melanoma prognostication by quantifying tumor burden through a simple, reproducible measurement. The Breslow index demonstrates a direct, close correlation with survival—the thicker the melanoma, the worse the prognosis 1.
This measurement supersedes other clinical parameters in prognostic value. While factors like sex, age, and lesion site have some prognostic significance, their value is substantially lower compared to Breslow thickness 1. The measurement is taken from the granular layer of the epidermis (or from the base of ulceration if present) to the deepest invasive melanoma cell 2.
Clinical Staging and Treatment Implications
The prognostic power of Breslow thickness directly drives clinical management decisions:
Surgical Margin Determination
Excision margins are stratified entirely by Breslow thickness 1, 3, 4:
- Melanoma in situ: 0.5 cm margin
- ≤1 mm: 1 cm margin
- 1-2 mm: 1-2 cm margins
- 2-4 mm: 2 cm margins
- >4 mm: 3 cm margins (some guidelines recommend 2 cm for >2 mm)
Sentinel Lymph Node Biopsy Eligibility
Breslow thickness determines who should undergo sentinel node biopsy. Patients with melanomas >0.8-1.0 mm thickness (or thinner melanomas with ulceration) are candidates for sentinel lymph node biopsy for accurate staging 5, 4. This threshold reflects the increased metastatic risk with deeper invasion.
Prognostic Stratification
The AJCC staging system incorporates Breslow thickness as the primary T-stage determinant 5, 6. Recent data confirm natural prognostic breakpoints, particularly at 0.8 mm, where a biologically-relevant difference in 10-year melanoma-specific survival emerges 7.
Nuances and Refinements
For Thin Melanomas (<1 mm)
In thin melanomas, Clark level (anatomic depth of invasion) retains prognostic value when Breslow thickness alone doesn't fully stratify risk 1, 6. However, mitotic rate has now replaced Clark level as the criterion for upstaging thin melanomas from stage IA to IB in modern staging systems 5.
Complementary Factors
While Breslow thickness remains dominant, other histologic features add prognostic information:
- Ulceration: The second most important primary tumor characteristic 5, 6
- Mitotic rate: Independent predictor of outcome, especially in melanomas ≤1.0 mm 5, 6
- Microsatellites: Frequency increases progressively with Breslow thickness (0.1% in T1 to 17.8% in T4 tumors), and their presence upstages disease to N1c 2
Emerging Concepts
Recent research suggests that Breslow thickness, while measuring tumor depth in one dimension, may not fully capture three-dimensional tumor burden. Studies show that tumor volume estimates and nuclear counts may provide additional prognostic value beyond Breslow thickness alone 8, 9, 10. However, Breslow thickness remains the established standard in clinical practice 11.
Critical Clinical Pitfall
Long-term follow-up is essential for thin melanomas. Counterintuitively, more melanoma deaths occur in patients with thin (T1) melanomas than thick melanomas because the vast majority of melanomas present as T1 tumors. Among T1 patients who die of melanoma, only 29.3% die within 5 years—the majority die later 7. This underscores that even "favorable" Breslow thickness requires sustained surveillance.
The Bottom Line
Breslow's hypothesis transformed melanoma management by providing an objective, reproducible measurement that directly predicts mortality and guides treatment intensity. For single excisable melanomas, Breslow thickness is the most powerful and most commonly used prognostic factor (Level of Evidence A) 1, forming the foundation upon which modern melanoma staging and treatment algorithms are built.